20 results
P
patients with chronic lymphocytic leukemia
I/C
ibrutinib-obinutuzumab (IO), venetoclax-obinutuzumab (VO), acalabrutinib (A), acalabrutinib plus obinutuzumab (AO), IO vs VO, A vs IO, A vs VO, AO vs IO, AO vs VO
O
progression-free survival (PFS)
P
healthy adults
I/C
physical activity, no physical activity
O
health-related quality of life (HRQOL), six minutes walking test (6MWT), oxygen consumption (VO
P
heart failure patients
I/C
Baduanjin exercise, no intervention
O
quality of life (QoL), cardiac function, and maximal oxygen consumption (VO
P
ALS patients
I/C
aerobic exercise training, resistance exercise training, combined exercise training, no exercise training
O
functional ability, respiratory function, fatigue, pain, quality of life, upper-body strength, lower-body strength, Vo
P
adults with overweight and obesity
I/C
aerobic exercise (AE), resistance training (RT), combined aerobic and resistance training (CT), high-intensity interval training (HIIT), no intervention
O
weight loss, body mass index, waist circumference, percentage body fat, serum triglycerides, fasting blood glucose, VO
P
seniors aged 65 years or over
I/C
high-intensity interval training (HIIT) and exercise training (ET)
O
peak oxygen uptake (VO2)
P
patients with coronary artery disease (CAD) and heart failure (HF)
I/C
high-intensity interval training (HIIT), moderate-intensity continuous training (MICT)
O
peak oxygen consumption (peak VO2)
P
triathletes
I/C
practice, cardiorespiratory and physiological measurements
O
performance level